TrianglePUBLICATIONS · 28083710
Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Cancer Res Clin Oncol
- Publication date
- 2017 Apr
- First author
- Lin JX
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Lin JX
- type
- Author
- name
- Chen QF
- type
- Author
- name
- Zheng CH
- type
- Author
- name
- Li P
- type
- Author
- name
- Xie JW
- type
- Author
- name
- Wang JB
- type
- Author
- name
- Lu J
- type
- Author
- name
- Chen QY
- type
- Author
- name
- Cao LL
- type
- Author
- name
- Lin M
- type
- Author
- name
- Tu RH
- type
- Author
- name
- Huang CM
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Lin JX
- type
- Author
- name
- Chen QF
- type
- Author
- name
- Zheng CH
- type
- Author
- name
- Li P
- type
- Author
- name
- Xie JW
- type
- Author
- name
- Wang JB
- type
- Author
- name
- Lu J
- type
- Author
- name
- Chen QY
- type
- Author
- name
- Cao LL
- type
- Author
- name
- Lin M
- type
- Author
- name
- Tu RH
- type
- Author
- name
- Huang CM
- type
- Author
- bibliography ids
- nci-bib-3b8e3494c27616f8962358df
- book metadata
- content sha256
- c9b237500867ec3cf7c67234f076a50627b576a0954c9c62ba4883159e5b17d1
- document type
- citation
- dois
- 10.1007/s00432-016-2334-x
- electronic publication date
- display
- 2017 Jan 12
- precision
- day
- year
- 2017
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:28083710
- immutable id
- pubmed:28083710@c9b237500867ec3cf7c67234f076a50627b576a0954c9c62ba4883159e5b17d1
- journal
- abbreviation
- J Cancer Res Clin Oncol
- issn electronic
- 1432-1335
- issn print
- 0171-5216
- issue
- 4
- name
- Journal of cancer research and clinical oncology
- nlm unique id
- 7902060
- pages
- 727-734
- volume
- 143
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 28083710
- provenance
- batch id
- 7a1288ac8bb5f9826304
- provider
- NCBI PubMed ESummary
- record sha256
- bf065ae927ad3d9f69d573e2d3067f931e8913d2877e2ede7389e8905f8120c8
- response sha256
- 0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
- retrieved at
- 2026-09-09T23:47:23.138359+00:00
- publication date
- display
- 2017 Apr
- precision
- month
- year
- 2017
- publication types
- Journal Article
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Preserved source evidence · Not medical advice